
This review considers the use of the first selective blocker of the zzso zzso type 1, zzso to reduce weight and improve cardiovascular disease risk factors in obese patients with zzso syndrome or multiple cardiovascular disease risk zzso In 4 large zzso in zzso zzso zzso zzso America, and zzso 1 to 2 years of treatment, zzso (20 zzso led to a significantly greater weight loss and reduction in waist circumference compared with zzso Treatment with zzso was also associated with other favorable changes, including better zzso control in type 2 diabetes zzso improved zzso profile, reduced blood pressure, increased zzso levels, fall in zzso zzso protein zzso and an overall decrease in the prevalence of the zzso zzso zzso experience with zzso shows that it is generally well tolerated with the most common side effect of mild zzso zzso may be a useful adjunct to lifestyle and behavior modification in the treatment of obese subjects with zzso syndrome or multiple zzso risk zzso 

